- Home
- CABA vs RIV Comparison
CABA vs RIV Comparison
Compare CABA & RIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CABA | RIV |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.6M | 315.3M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | CABA | RIV |
|---|---|---|
| Price | $3.01 | $11.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 4.1M | 68.8K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.85% |
| EPS Growth | ★ 10.26 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $10.93 |
| 52 Week High | $4.23 | $12.56 |
Technical Indicators
Market Signals| Indicator | CABA | RIV |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 48.49 |
| Support Level | $2.11 | $11.28 |
| Resistance Level | $3.48 | $11.84 |
| Average True Range (ATR) | 0.26 | 0.17 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 21.12 | 47.31 |
Price Performance
Historical ComparisonAbout CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
About RIV RiverNorth Opportunities Fund Inc.
Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.